[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Xijing Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":583},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,130,0,25,[9,41,64,90,112,130,149,174,194,216,245,271,292,311,336,364,386,408,427,451,470,491,511,531,552],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100652141","a-multicenter-prospective-observational-cohort-study-for-digestive-tract-tumor-screening-using-multi-target-blood-and-fecal-biomarkers-100652141",false,"NCT07769892","A Multicenter Prospective Observational Cohort Study for Digestive Tract Tumor Screening Using Multi-Target Blood and Fecal Biomarkers","A Multicenter Prospective Observational Cohort Study on Digestive Tract Tumor Screening Based on Combined Detection of Multi-Target Blood and Fecal Biomarkers","Inclusion Criteria:\n\n* 1.Subjects aged 45-74 years at enrollment; 2.Scheduled to undergo digestive tract endoscopic screening; 3.Agree to receive five-year follow-up in accordance with the study protocol; 4.Willing to provide written informed consent.\n\nExclusion Criteria:\n\n* 1\\. Having received upper gastrointestinal endoscopy within one year; 2.History of any type of malignant tumor; 3.Complicated with severe illnesses that reduce screening benefits, such as severe pulmonary, renal, hepatic, cardiovascular, cerebrovascular and hematological diseases; 4.Other conditions assessed by physicians as excessively high risk for endoscopic screening (e.g., hemodynamic instability) or non-beneficial (short life expectancy); 5.Pregnant or lactating women.",true,"ALL","45 Years","74 Years",{"count":22,"type":23},5000,"ESTIMATED","OBSERVATIONAL","This project aims to evaluate the sensitivity and specificity of combined blood multi-gene methylation and fecal biomarkers for pan-digestive tract cancer screening, so as to establish a novel technical system for the early diagnosis of pan-digestive tract cancers.Individuals scheduled to receive digestive tract endoscopy are enrolled. Blood and stool samples are collected prior to endoscopic examination for detection of blood multi-gene methylation, fecal immunochemical test (FIT) and calprotectin. Endoscopic procedures are then performed. Following completion of baseline endoscopic screening, all enrolled participants will be followed up for 5 years. The primary endpoint of this study is the sensitivity and specificity of blood multi-gene methylation combined with fecal biomarkers in screening for pan-digestive tract cancers.",[27],"Gastrointestinal Cancers","RECRUITING","2026-08-17",{"date":31,"type":32},"2026-08-18","ACTUAL",{"date":34,"type":23},"2026-08-10",{"date":36,"type":23},"2035-12-31",{"name":38,"class":39},"Xijing Hospital","OTHER",7,{"id":42,"slug":43,"hasResults":12,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":51,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":62,"locationsCount":63},"100647710","a-study-on-gastrointestinal-cancer-screening-using-a-multi-targeted-combined-detection-model-100647710","NCT07712107","A Study on Gastrointestinal Cancer Screening Using a Multi-Targeted Combined Detection Model","A Study on Gastrointestinal Cancer Screening Using a Multi-Targeted Combined Detection Model: A Multi-center Prospective Randomized Controlled Trial","Inclusion Criteria:\n\n* Participants must be between 45 and 74 years of age at the time of enrollment;\n* Participants must agree to be randomly assigned to different screening and follow-up strategies;\n* Participants must agree to undergo a five-year follow-up in accordance with the protocol;\n* Participants must be willing to participate and sign an informed consent form.\n\nExclusion Criteria:\n\n* Underwent upper gastrointestinal endoscopy screening within the past year;\n* History of any type of malignant tumor;\n* Concurrent severe medical conditions that reduce the benefits of screening, such as severe pulmonary disease, kidney disease, liver disease, cardiovascular and cerebrovascular diseases, and hematological disorders;\n* Other situations where a physician determines that endoscopic screening poses excessive risk (e.g., hemodynamic instability) or offers no benefit (e.g., short life expectancy);\n* Pregnant or breastfeeding women.",{"count":49,"type":23},10000,"INTERVENTIONAL",[52],"NA","This study is a multicenter, randomized controlled trial. The plan is to enroll eligible participants and randomly assign them to two groups: one group will undergo testing using a combined model of \"multi-target blood methylation + fecal FIT + fecal calpetin\"; those with positive results will immediately undergo standard gastrointestinal endoscopy, while those with negative results will enter routine observation; the other group will undergo only routine observation and follow-up. All enrolled participants will undergo a 5-year prospective follow-up, during which information on gastrointestinal cancer incidence and mortality will be collected through regular contact and review of medical records. The primary endpoint of the study is the difference in 5-year all-gastrointestinal cancer mortality between the two groups.This project aims to use a randomized controlled trial design to evaluate whether an active screening strategy based on a combined model can effectively reduce the population-level mortality from gastrointestinal cancers compared to routine surveillance. The objective is to provide high-level evidence for establishing a new screening strategy that reduces the disease burden and delivers public health benefits. It lays the foundation for validating novel biomarkers and exploring the biological and behavioral factors that influence screening outcomes, and offers clear decision-making support for optimizing China's comprehensive prevention and control system for gastrointestinal cancers.",[55],"Gastrointestinal Tumors","2026-08-12",{"date":58,"type":32},"2026-08-14",{"date":60,"type":32},"2026-06-15",{"date":36,"type":23},{"name":38,"class":39},6,{"id":65,"slug":66,"hasResults":12,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":4,"eligibilityCriteria":70,"healthyVolunteers":12,"sex":71,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":4,"studyType":50,"phases":76,"briefSummary":78,"conditions":79,"keywords":81,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":83,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},"100586366","phase-2-neoadjuvant-sbrt-followed-by-nab-paclitaxel-combined-with-toripalimab-in-hrher2--breast-cancer-100586366","NCT06914440","Neoadjuvant SBRT Followed by Nab-Paclitaxel Combined With Toripalimab in HR+\u002FHER2- Breast Cancer","Neoadjuvant SBRT Followed by Nab-Paclitaxel Combined With Toripalimab in HR+\u002FHER2- Breast Cancer: A Single-arm, Prospective Clinical Trial","Inclusion Criteria:\n\n1. Female patients aged ≥18 and ≤75 years at the time of signing informed consent.\n2. ECOG PS status of 0-1.\n3. Histologically confirmed non-metastatic (M0) breast cancer, meeting all of the following:\n\n   a) Clinical stage (per AJCC 8th edition) meeting one of the following: i. cT3N0, cT2-4N1-3, or cT1N2-3 (Stage IIB, IIIA, IIIB, or IIIC); ii. cT2N0 or cT1N1 (Stage IIA) with at least two of the following high-risk features: Histologic grade 3; Ki-67 ≥50%; Age \\\u003C50 years and premenopausal status.\n\n   b) Imaging assessments within 28 days prior to enrollment including: abdominal CT or ultrasound, bone scan (ECT), chest CT, and brain MRI.\n4. Histologically or pathologically confirmed invasive carcinoma, with all of the following:\n\n   1. Grade 2 or 3 (confirmed by central laboratory);\n   2. ER-positive (\\>1% staining) and\u002For PR-positive (\\>1% staining) by IHC;\n   3. HER2-negative (IHC 0\u002F1+ or HER2\u002Fneu FISH ratio ≤1.8);\n   4. Ki-67 ≥15%.\n5. Patient deemed eligible for radiotherapy after MDT evaluation.\n6. No prior antitumor therapy within 1 month before enrollment.\n7. Organ Function Requirements (within 7 days prior to enrollment):\n\n   1. Complete blood count (no transfusion or hematopoietic growth factors within 7 days): ANC ≥1.5×10⁹\u002FL; ALC ≥0.5×10⁹\u002FL; Platelets ≥100×10⁹\u002FL; Hemoglobin ≥90 g\u002FL; WBC ≥3.0×10⁹\u002FL and ≤15×10⁹\u002FL;\n   2. Blood biochemistry (no transfusion\u002Falbumin within 7 days): ALT\u002FAST ≤2.5×ULN; ALP ≤2.5×ULN；BUN\u002FCr ≤1.5×ULN; Cr≥60 mL\u002Fmin (Cockcroft-Gault formula);\n   3. Coagulation: PT\u002FAPTT ≤1.5×ULN; INR ≤1.5×ULN (if no anticoagulant therapy);\n   4. Urinalysis: Urine protein \\\u003C2+; if ≥2+, 24-hour urine protein must be ≤1g;\n   5. Thyroid function:TSH ≤1×ULN; if abnormal, normal T3\u002FT4 levels required for eligibility.\n8. Women of childbearing potential must:\n\n   1. Have a negative serum pregnancy test within 7 days before treatment;\n   2. Use highly effective contraception during the study and for 180 days after the last dose.\n9. Voluntarily sign informed consent, demonstrate good compliance, and commit to follow-up.\n\nExclusion Criteria:\n\n1. Inflammatory Breast Cancer.\n2. Comorbidities\u002FMedical History:\n\n   1. Autoimmune disease: patients with any known or suspected autoimmune disease, except: hypothyroidism due to autoimmune thyroiditis managed with hormone replacement therapy only, stable type-1 diabetes with well-controlled blood glucose.\n   2. Cardiovascular Diseases: poorly controlled hypertension despite medication (SBP \\>140 mmHg or DBP\\>90 mmHg). And with the history (within 6 months prior to enrollment) of myocardial infarction, severe\u002Funstable angina, NYHA Class ≥2 heart failure, clinically significant arrhythmias as well as symptomatic congestive heart failure.\n   3. Interstitial lung disease, non-infectious pneumonitis, or other uncontrolled systemic diseases (e.g., diabetes, pulmonary fibrosis, acute pneumonia);\n   4. Vaccination: receipt of live attenuated vaccines within 28 days prior to enrollment or planned during the study;\n   5. Infections: HIV\u002FAIDS, active hepatitis(HBV-DNA ≥500 IU\u002FmL; HCV-RNA above detection limit), or co-infection with HBV and HCV, severe infections within 4 weeks prior to enrollment (e.g., bacteremia, severe pneumonia requiring hospitalization), active infection requiring systemic antibiotics (CTCAE≥Grade 2) within 2 weeks prior to treatment, active tuberculosis within 1 year prior to enrollment;\n   6. Unexplained fever \\>38.5°C during screening (unless deemed tumor-related by the investigator);\n   7. Malignancy History: other malignancies diagnosed within 5 years prior to enrollment (except adequately treated basal cell carcinoma, squamous cell skin cancer, or cervical carcinoma in situ);\n   8. Surgery:Major surgery within 28 days prior to enrollment (diagnostic biopsies or PICC line placement are allowed);\n   9. Transplant: Prior or planned allogeneic bone marrow or solid organ transplant;\n   10. Neurological: peripheral neuropathy ≥Grade 2;\n   11. Gastrointestinal: clinically significant bowel obstruction;\n   12. Thrombotic Events: arterial\u002Fvenous thrombosis within 6 months prior to enrollment (e.g., stroke, transient ischemic attack, DVT, pulmonary embolism);\n   13. Bleeding Risk: hemoptysis (≥2.5 mL\u002Fday) within 2 months prior to enrollment, clinically significant bleeding within 3 months prior to enrollment (e.g. gastrointestinal bleeding, hemorrhagic gastric ulcer, baseline fecal occult blood≥++), and the known bleeding\u002Fthrombotic disorders (e.g., hemophilia, coagulopathy, thrombocytopenia, hypersplenism);\n   14. Coagulation abnormalities (INR \\>1.5×ULN or APTT \\>1.5×ULN), or requiring long-term anticoagulation (warfarin\u002Fheparin) or antiplatelet therapy (aspirin≥300 mg\u002Fday or clopidogrel ≥75 mg\u002Fday).\n3. Treatment-Related Exclusions:\n\n   1. Prior systemic targeted therapy or immunostimulants (e.g., interferon, IL-2) within 4 weeks before treatment;\n   2. Known allergy to the investigational drug (recombinant humanized anti-PD-1 mAb) or its excipients.\n4. Clinical Trial Participation: participation in another drug trial within 4 weeks prior to enrollment, or within 5 half-lives of the last investigational drug dose.\n5. Substance Abuse: history of drug\u002Falcohol abuse or dependency.\n6. Pregnancy\u002FLactation: pregnant, breastfeeding, or planning pregnancy during the study.\n7. Investigator' s Discretion: other conditions that may compromise subject safety or study integrity (e.g., severe lab abnormalities, social factors).","FEMALE","18 Years","75 Years",{"count":75,"type":23},27,[77],"PHASE2","The goal of this clinical trial is to evaluate the efficacy and safety of neoadjuvant stereotactic body radiotherapy (SBRT) followed by nab-paclitaxel combined with toripalimab in patients with previously untreated HR+\u002FHER2-negative breast cancer. Eligible patients include those with stage IIB-IIIC disease (cT3N0, cT2-4N1-3 or cT1N2-3) or stage IIA disease (cT2N0 or cT1N1) with at least two of the following high-risk factors: histologic grade 3, Ki-67 ≥50% or premenopausal with age \\\u003C50 years. A total of 27 enrolled patients will be assigned to receive the combination therapy. The primary question it aims to answer is whether this combination of radiotherapy, de-escalated chemotherapy, and immunotherapy can improve the total pathologic complete response (tpCR) rate (defined as ypT0\u002FTis ypN0).",[80],"Breast Cancer",[80,82],"Neoadjuvant therapy",{"date":58,"type":32},{"date":85,"type":32},"2025-06-05",{"date":87,"type":23},"2030-12",{"name":38,"class":39},2,{"id":91,"slug":92,"hasResults":12,"nctId":93,"briefTitle":94,"officialTitle":94,"acronym":4,"eligibilityCriteria":95,"healthyVolunteers":12,"sex":18,"minAge":72,"maxAge":4,"enrollmentInfo":96,"targetDuration":4,"studyType":50,"phases":98,"briefSummary":99,"conditions":100,"keywords":102,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":108,"leadSponsor":110,"locationsCount":111},"100650717","a-randomized-controlled-open-label-multi-center-clinical-study-comparing-the-efficacy-of-close-follow-up-versus-adjuvant-chemotherapy-in-patients-with-stage-ib-iia-gastric-or-gastroesophageal-junction-adenocarcinoma-following-radical-surgery-100650717","NCT07751302","A Randomized, Controlled, Open-Label, Multi-center Clinical Study Comparing the Efficacy of Close Follow-Up Versus Adjuvant Chemotherapy in Patients With Stage IB-IIA Gastric or Gastroesophageal Junction Adenocarcinoma Following Radical Surgery","Inclusion Criteria:\n\n* 1.Aged ≥18 years of either gender. 2.Histologically confirmed adenocarcinoma of the stomach or gastroesophageal junction with an ECOG performance status score ≤2.\n\n  3.Pathologic TNM stage IB-IIA gastric or gastroesophageal junction adenocarcinoma, excluding T2N1.\n\n  4.Curative surgical resection of the primary tumor completed. 5.Laboratory test criteria as below:\n  1. Absolute neutrophil count (ANC) ≥1.5×10⁹\u002FL without granulocyte colony-stimulating factor administration within the preceding 14 days;\n  2. Platelet count ≥100×10⁹\u002FL without blood transfusion within the preceding 14 days;\n  3. Hemoglobin \\>9 g\u002FdL without blood transfusion or erythropoietin administration within the preceding 14 days;\n  4. Total bilirubin ≤1.5×upper limit of normal (ULN);\n  5. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5×ULN;\n  6. Serum creatinine ≤1.5×ULN and calculated creatinine clearance (Cockcroft-Gault formula) ≥60 mL\u002Fmin;\n  7. Adequate coagulation function: international normalized ratio (INR) or prothrombin time (PT) ≤1.5×ULN;\n  8. Cardiac biomarkers within normal range; isolated laboratory abnormalities deemed clinically insignificant by the investigator are acceptable.\n\n     6.Voluntary participation and written informed consent obtained prior to study enrollment\n\n     Exclusion Criteria:\n* 1\\. Other malignant tumors of the stomach. 2. Receipt of any anti-tumor therapy other than the chemotherapy specified in this protocol prior to screening or planned administration of such therapy during the trial (including radiotherapy, targeted therapy, immunotherapy, etc.).\n\n  3\\. Concurrent or prior malignancy at other anatomic sites, except for adequately treated carcinoma in situ of cervix, basal cell carcinoma of skin, or other malignancies surgically cured with no disease recurrence for at least 5 years.\n\n  4\\. Presence of any severe or uncontrolled systemic diseases as follows:\n  1. Unstable angina, congestive heart failure, or chronic heart failure classified as NYHA Grade ≥Ⅱ.\n  2. Resting electrocardiogram showing severe, symptomatic and refractory abnormalities in cardiac rhythm, conduction or morphology, including complete left bundle branch block, second-degree or higher atrioventricular block, ventricular arrhythmia or atrial fibrillation.\n  3. History of arterial thrombosis, embolism or ischemic events within 6 months before enrollment, such as myocardial infarction, unstable angina, cerebrovascular accident or transient ischemic attack.\n  4. Poorly controlled hypertension (systolic BP\\>140 mmHg, diastolic BP\\>90 mmHg).\n  5. History of non-infectious pneumonia requiring glucocorticoid treatment within 1 year prior to first study drug administration, or clinically active interstitial lung disease at screening.\n  6. Active pulmonary tuberculosis.\n  7. Active or uncontrolled infection requiring systemic treatment.\n  8. Clinically active diverticulitis, intra-abdominal abscess or gastrointestinal obstruction.\n  9. Hepatic diseases including liver cirrhosis, decompensated liver disease, acute or chronic active hepatitis.\n  10. Poorly controlled diabetes mellitus (fasting blood glucose, FBG\\>10 mmol\u002FL).\n  11. Urinalysis showing ≥2+ proteinuria confirmed by 24-hour urinary protein quantification\\>1.0 g.\n  12. Psychiatric disorders rendering the subject unable to comply with study treatment.\n\n      5\\. Current participation in another clinical trial or participation in any other clinical trial within the preceding 3 months.\n\n      6\\. Known hypersensitivity to any investigational drugs used in this study. 7. Subjects deemed ineligible for enrollment at the Investigator's discretion.",{"count":97,"type":23},500,[52],"This study is a randomized, controlled, open-label, multicenter trial. Patients who underwent radical resection for stage IB-IIA gastric or gastroesophageal junction adenocarcinoma were enrolled and stratified into low-risk and high-risk groups based on the presence of lymph node metastasis, vascular invasion, or elevated preoperative tumor markers (CEA or CA19-9). Patients in the low-risk group were directly enrolled in follow-up observation, while those in the high-risk group were randomized 1:1 to either close follow-up or adjuvant chemotherapy. The primary endpoint of the study is the efficacy and safety of adjuvant chemotherapy following radical resection in patients with stage IB-IIA gastric or gastroesophageal junction adenocarcinoma.",[101],"Stage IB-IIA Adenocarcinoma of the Stomach or Gastroesophageal Junction",[103],"Stage IB-IIA adenocarcinoma of the stomach or gastroesophageal junction","2026-08-06",{"date":106,"type":32},"2026-08-07",{"date":34,"type":23},{"date":109,"type":23},"2036-01-31",{"name":38,"class":39},1,{"id":113,"slug":114,"hasResults":12,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":17,"sex":18,"minAge":72,"maxAge":4,"enrollmentInfo":119,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":120,"conditions":121,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":126,"leadSponsor":128,"locationsCount":129},"100638058","evaluation-of-fecal-multi-target-biomarkers-in-the-screening-of-digestive-tract-cancers-100638058","NCT07600125","Evaluation of Fecal Multi-target Biomarkers in the Screening of Digestive Tract Cancers","Evaluation of Fecal Multi-target Biomarkers in the Screening of Digestive Tract Cancers: a Multi-center Prospective Observational Cohort Study","Inclusion Criteria:\n\n1. Participants must be at least 18 years of age at the time of enrollment;\n2. Participants must be scheduled to undergo gastroscopy and colonoscopy;\n3. Participants must agree to undergo a two-year follow-up as outlined in the protocol;\n4. Participants must be willing to participate and sign an informed consent form.\n\nExclusion Criteria:\n\n1. Have undergone gastrointestinal endoscopy screening within the past year;\n2. History of any type of gastrointestinal malignancy;\n3. Concurrent severe medical conditions that reduce the benefits of screening, such as severe pulmonary disease, kidney disease, liver disease, cardiovascular and cerebrovascular diseases, and hematological disorders;\n4. Other situations where a physician determines that endoscopic screening poses excessive risk (e.g., hemodynamic instability) or offers no benefit (e.g., short life expectancy);\n5. Pregnant or breastfeeding women.",{"count":22,"type":23},"This study is a multi-center, observational study. Participants scheduled for gastroscopy and colonoscopy will undergo an epidemiological assessment and provide a stool sample prior to endoscopy for qualitative Fecal Immunochemical Test (FIT), quantitative Fecal Immunochemical Test (FIT), and novel biomarker testing, followed by the endoscopic examination. After completion of the baseline endoscopic screening, all enrolled participants will undergo a 2-year follow-up. The primary endpoints of the study are sensitivity and specificity for the screening of gastrointestinal cancers.The aim of this study is to develop and evaluate the sensitivity and specificity of fecal multi-marker panels for the screening of gastrointestinal cancers.",[122],"Gastric Cancer, Colorectal Cancer",{"date":124,"type":32},"2026-08-11",{"date":34,"type":23},{"date":127,"type":23},"2027-12-31",{"name":38,"class":39},13,{"id":131,"slug":132,"hasResults":12,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":4,"eligibilityCriteria":136,"healthyVolunteers":12,"sex":18,"minAge":72,"maxAge":4,"enrollmentInfo":137,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":138,"conditions":139,"keywords":4,"overallStatus":141,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":4},"100648198","early-postoperative-l-arginine-and-acute-kidney-injury-after-cardiac-surgery-100648198","NCT07718373","Early Postoperative L-arginine and Acute Kidney Injury After Cardiac Surgery","Early Postoperative L-arginine and Acute Kidney Injury After Cardiac Surgery: a Target Trial Emulation","Inclusion Criteria:\n\n·adults admitted to the ICU after CPB-assisted cardiac surgery\n\nExclusion Criteria:\n\n* congenital heart disease,\n* surgery requiring deep hypothermic circulatory arrest,\n* a preoperative baseline estimated glomerular filtration rate (eGFR) below 30 mL\u002Fmin\u002F1.73 m²,\n* AKI already present prior to ICU admission",{"count":22,"type":23},"Acute kidney injury (AKI) is common after cardiac surgery, yet effective protective strategies remain limited. L-arginine is the substrate for endogenous nitric oxide (NO) synthesis and may improve renal perfusion and endothelial function. investigators emulated a target trial to evaluate whether early perioperative L-arginine was associated with a lower risk of AKI after cardiac surgery.",[140],"Acute Kidney Injury","NOT_YET_RECRUITING","2026-08-05",{"date":34,"type":32},{"date":145,"type":23},"2026-07-20",{"date":147,"type":23},"2026-08-20",{"name":38,"class":39},{"id":150,"slug":151,"hasResults":12,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":4,"eligibilityCriteria":155,"healthyVolunteers":12,"sex":18,"minAge":156,"maxAge":157,"enrollmentInfo":158,"targetDuration":4,"studyType":50,"phases":160,"briefSummary":161,"conditions":162,"keywords":164,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":168,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":111},"100573169","the-feasibility-of-tavns-on-pregnancy-outcomes-of-infertility-patients-undergoing-ivf-100573169","NCT06742788","The Feasibility of taVNS on Pregnancy Outcomes of Infertility Patients Undergoing IVF","The Feasibility of Transcutaneous Auricular Vagus Nerve Stimulation on Pregnancy Outcomes of Infertility Patients Undergoing in Vitro Fertilization: Study Protocol for a Pilot Randomized Controlled Trial","Inclusion Criteria:\n\n1. Subjects aged 20 to 40 years, diagnosed with infertility, and preparing to undergo IVF treatment;\n2. Female subjects with anti-Müllerian hormone (AMH) \\> 1.2 ng\u002FmL;\n3. Scoring at mild-to-moderate levels of impairment on anxiety, and depression scales;\n4. Both the subject and their family sign the informed consent form.\n\nExclusion Criteria:\n\n1. The subject had been treated with taVNS in the past;\n2. Subjects preparing to undergo frozen embryo transfer;\n3. Subjects with a history of mental disorder or who score at a severe level of impairment on anxiety and depression scales;\n4. Taking sedatives, anxiety, depression, or psychiatric medications;\n5. Comorbidities including arrhythmia, hypertension, diabetes, chronic heart and kidney diseases;\n6. Ineligibility for enrollment assessed by a gynecologist or neurologist;\n7. Metallic implants or devices contraindicating taVNS.","20 Years","40 Years",{"count":159,"type":23},90,[52],"To assess the feasibility of taVNS on pregnancy outcomes of infertility subjects undergoing IVF, the primary aim of this trial will focus on encompassing recruitment, compliance, and preliminary engagement outcomes.\n\nThe exploratory aim is to carry out clinical research, which entails evaluating the preliminary effects of the intervention in order to ascertain its potential benefits.\n\nThe main question it aims to answer is: Does the taVNS is feasible and tolerated in the context of IVF?\n\nWhat medical problems do participants have when using the taVNS device? Researchers will compare the taVNS to the sham transcutaneous auricular vagus nerve stimulation (a look-alike device that produces a sub-threshold therapeutic stimulus and functions as a sham stimulus) and blank control to see if the taVNS device works to enhance outcomes of IVF.\n\nParticipants will:\n\nUse the device a total of 1.5 hours daily, with the sessions divided into three parts, each lasting 30 minutes. At least one of these periods occur within 2 hours before bedtime.\n\nVisit the clinic according to the scheduled treatment time points of IVF. Keep a diary of their adverse events and the number of times they use the device.",[163],"Infertility Assisted Reproductive Technology",[165,166,167],"Infertility","Assisted Reproductive Techniques","Transcutaneous Auricular Vagus Nerve Stimulation",{"date":104,"type":32},{"date":170,"type":32},"2025-03-04",{"date":172,"type":23},"2027-12-30",{"name":38,"class":39},{"id":175,"slug":176,"hasResults":12,"nctId":177,"briefTitle":178,"officialTitle":178,"acronym":179,"eligibilityCriteria":180,"healthyVolunteers":12,"sex":18,"minAge":72,"maxAge":4,"enrollmentInfo":181,"targetDuration":4,"studyType":50,"phases":183,"briefSummary":184,"conditions":185,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":111},"100650525","phase-2-single-arm-phase-ii-clinical-study-evaluating-the-safety-and-efficacy-of-sintilimab-combined-with-ibi-310-and-chemotherapy-as-neoadjuvant-therapy-for-locally-advanced-rectal-cancer-100650525","NCT07750951","Single-arm, Phase II Clinical Study Evaluating the Safety and Efficacy of Sintilimab Combined With IBI-310 and Chemotherapy as Neoadjuvant Therapy for Locally Advanced Rectal Cancer","sintilimab","Inclusion Criteria:\n\n* 1\\) Sign written informed consent before implementing any trial related processes;\n* 2\\) Male or female, age ≥ 18 years;\n* 3\\) ECOG score 0-1;\n* 4\\) The primary lesion is a locally advanced rectal adenocarcinoma with histopathologically confirmed MSI-H\u002FdMMR characteristics.;\n* 5\\) Combined with endoscopic ultrasonography \u002F rectal MR scan diagnosis, patients with clinical stage t2-4a or n+m0 were evaluated for lesion resectability;\n* 6\\) According to the response evaluation criteria for solid tumors (RECIST version 1.1), there was at least one measurable lesion on imaging;\n* 7\\) The patient has not received any anti-tumor treatment in the past, including but not limited to surgery, radiotherapy, chemotherapy, immunotherapy, targeted therapy Therapeutics et al;\n* 8\\) Sufficient organ function, subjects need to meet the following laboratory indicators:\n\n  1. The absolute neutrophil count (ANC)≥1.5x109\u002FL without granulocyte colony stimulating factor in the past 14 days;\n  2. Platelets≥100×109\u002FL without blood transfusion in recent 14 days;\n  3. Hemoglobin \\>9g\u002Fdl without blood transfusion or use of erythropoietin in recent 14 days;\n  4. Total bilirubin ≤ 1.5×upper limit of normal (ULN);\n  5. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT)≤2.5×ULN;\n  6. Serum creatinine≤1.5×ULN and creatinine clearance (calculated by Cockcroft Gault formula)≥60ml\u002Fmin;\n  7. Good coagulation function, defined as international normalized ratio (INR) or prothrombin time (PT)≤1.5times ULN;\n  8. Thyroid function was normal, defined as thyroid stimulating hormone (TSH) within the normal range. If baseline TSH is outside the normal range, subjects with total T3 (or FT3) and FT4 within the normal range can also be enrolled;\n  9. The myocardial enzyme spectrum is within the normal range (for example, simple laboratory abnormalities that are not clinically significant according to the comprehensive judgment of the investigator are also allowed to be enrolled).\n* 9\\) Female subjects of childbearing age should receive a urine or serum pregnancy test with negative results within 3 days before receiving the first study drug administration (day 1 of cycle 1). If the urine pregnancy test result cannot be confirmed as negative, a blood pregnancy test is required. Women of non reproductive age were defined as having been postmenopausal for at least 1 year, or having undergone surgical sterilization or hysterectomy;\n* 10\\) If there is a risk of conception, all subjects (whether male or female) need to use contraceptive measures with an annual failure rate of less than 1% during the whole treatment period until 120 days after the last dose of study drug (or 180 days after the last dose of chemotherapy drug).\n\nExclusion Criteria:\n\n* 1\\) Diagnose distant metastasis through CT\u002FMR\u002FEUS;\n* 2\\) Other malignant tumors (excluding basal cell or squamous cell carcinoma, superficial bladder cancer, cervical carcinoma in situ or breast cancer) in the past 5 years;\n* 3\\) Severe intestinal obstruction;\n* 4\\) Currently participating in interventional clinical research treatment, or having received other investigational drugs or used investigational devices within 4 weeks prior to the first administration;\n* 5\\) Previously received the following therapies: anti-PD-1, anti-PD-L1, or anti-PD-L2 drugs, or drugs that stimulate or synergistically inhibit T cell receptors (such as CTLA-4, OX-40, CD137);\n* 6\\) Within 2 weeks before the first administration, he has received systematic systemic treatment with traditional Chinese patent medicines and simple preparations with anti-tumor indications or drugs with immunomodulatory effects (including thymosin, interferon, interleukin, except for local use to control pleural effusion);\n* 7\\) An active autoimmune disease requiring systemic treatment (such as the use of disease relieving drugs, corticosteroids, or immunosuppressants) has occurred within 2 years prior to the first administration. Alternative therapies (such as thyroid hormone, insulin, or physiological glucocorticoids used for adrenal or pituitary insufficiency) are not considered systemic treatments;\n* 8\\) Within 7 days prior to the first administration of the study, the individual was receiving systemic corticosteroid therapy (excluding topical corticosteroids via nasal spray, inhalation, or other routes) or any other form of immunosuppressive therapy; Note: Physiological doses of glucocorticoids (≤ 10 mg\u002Fday of prednisone or equivalent) are allowed to be used;\n* 9\\) Known allogeneic organ transplantation (excluding corneal transplantation) or allogeneic hematopoietic stem cell transplantation;\n* 10\\) Individuals who are known to be allergic to the active ingredients or excipients of the investigational drug Xindilimumab, IBI310;\n* 11\\) Individuals with multiple factors that affect oral medication, such as inability to swallow, post gastrointestinal resection, chronic diarrhea, and intestinal obstruction;\n* 12\\) Not fully recovered from toxicity and\u002For complications caused by any intervention measures before starting treatment (i.e. ≤ grade 1 or baseline, excluding fatigue or hair loss);\n* 13\\) Known history of human immunodeficiency virus (HIV) infection (i.e. HIV1\u002F2 antibody positive);\n* 14\\) Active hepatitis B without treatment (defined as HBsAg positive and HBV-DNA copy number detected is greater than the upper limit of normal value in the laboratory of the research center);\n\nNote: hepatitis B patients who meet the following criteria can also be included in the group:\n\n1. Prior to the first administration, if the HBV viral load is less than 1000 copies\u002Fml (200 IU\u002Fml), subjects should receive anti HBV treatment throughout the entire study chemotherapy period to avoid viral reactivation;\n2. For subjects with anti HBc (+), HBsAg (-), anti HBs (-), and HBV viral load (-), prophylactic anti HBV treatment is not necessary, but close monitoring of viral reactivation is required;\n3. Active HCV infected subjects (HCV antibody positive and HCV-RNA level above the detection limit);\n\n   * 15\\) Vaccination with live vaccine within 30 days prior to the first administration (Day 1 of the first cycle); Note: It is allowed to receive inactivated vaccine for seasonal influenza within 30 days before the first administration; However, intranasal administration of attenuated live influenza vaccine is not allowed.\n   * 16\\) Pregnant or lactating women;\n   * 17\\) There are any serious or uncontrollable systemic diseases, such as:\n\na) Resting electrocardiogram shows significant and difficult to control abnormalities in rhythm, conduction, or morphology, such as complete left bundle branch block, grade II or higher heart block, ventricular arrhythmia, or atrial fibrillation; b) Unstable angina pectoris, congestive heart failure, chronic heart failure classified as NYHA ≥ 2; c) Myocardial infarction occurred within 6 months prior to randomization; d) Poor blood pressure control (systolic blood pressure\\>140 mmHg, diastolic blood pressure\\>90 mmHg); e) A history of non infectious pneumonia requiring corticosteroid treatment within the year prior to the first administration, or current clinical active interstitial lung disease; f) Active pulmonary tuberculosis; g) There are active or uncontrolled infections that require systemic treatment; h) There is clinical active diverticulitis, abdominal abscess, and gastrointestinal obstruction; i) Liver diseases such as cirrhosis, decompensated liver disease, acute or chronic active hepatitis; j) Poor control of diabetes (FBG\\>10mmol\u002FL); k) Urine routine shows urinary protein ≥++and confirms 24-hour urinary protein quantification\\>1.0 g; l) Patients with mental disorders who are unable to cooperate with treatment;\n\n* 18\\) Medical history or disease evidence, abnormal treatment or laboratory test values that may interfere with the trial results, hinder the full participation of the subjects in the study, or other situations that the researchers believe are not suitable for inclusion. The researchers believe that there are other potential risks and they are not suitable to participate in this study.",{"count":182,"type":23},34,[77],"Observation and evaluation of the safety and efficacy of PD-1 antibody combined with IBI310 and neoadjuvant chemotherapy in the treatment of locally advanced rectal cancer\n\nPrimary objectives:\n\nPathological complete response (pCR) rate;\n\nSecondary objectives:\n\nTreatment-related adverse events (CTCAE 5.0), clinical complete response (cCR) rate, major pathological response (MPR) rate, R0 resection rate, sphincter preservation rate, surgical complications, 3-year disease-free survival (DFS), and overall survival (OS);",[186],"MSI-H\u002FdMMR Locally Advanced Rectal Adenocarcinoma","2026-08-03",{"date":104,"type":32},{"date":190,"type":32},"2026-05-29",{"date":192,"type":23},"2027-04",{"name":38,"class":39},{"id":195,"slug":196,"hasResults":12,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":200,"eligibilityCriteria":201,"healthyVolunteers":12,"sex":18,"minAge":202,"maxAge":203,"enrollmentInfo":204,"targetDuration":4,"studyType":50,"phases":206,"briefSummary":207,"conditions":208,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":210,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":111},"100649000","temporal-interference-stimulation-of-hypothalamus-in-patients-with-narcolepsy-type-1-100649000","NCT07727239","Temporal Interference Stimulation of Hypothalamus in Patients With Narcolepsy Type 1","Efficacy and Safety of Temporal Interference Stimulation of Hypothalamus in Patients With Narcolepsy Type 1: A Randomised, Double-blind, Sham-Controlled, Single-Centre Trial","TINY","Inclusion Criteria:\n\n* Aged 12 to 60 years.\n* Diagnosis of narcolepsy type 1 according to the International Classification of Sleep Disorders, Third Edition (ICSD-3), confirmed by polysomnography (PSG) and\u002For Multiple Sleep Latency Test (MSLT) performed within the past 10 years, with the test procedures meeting the minimum technical standards specified in the ICSD-3.\n* Epworth Sleepiness Scale score \\>12 at baseline.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Presence of other conditions that cause excessive daytime sleepiness, including restless legs syndrome, periodic limb movement disorder, or moderate-to-severe obstructive sleep apnea syndrome, etc.\n* History of epilepsy, severe neuropsychiatric disorders, or significant cardiac, hepatic, or renal dysfunction.\n* Pregnancy or current breastfeeding.\n* Contraindications to MRI or electrical stimulation therapy, such as intracranial metallic foreign bodies, cardiac pacemakers, implantable cardioverter-defibrillators, or cochlear implants.","12 Years","60 Years",{"count":205,"type":23},24,[52],"Narcolepsy type 1 (NT1) is a chronic brain disorder caused by selective loss or dysfunction of orexin (hypocretin) neurons in the lateral hypothalamus, for which current pharmacological treatments offer limited efficacy. Temporal interference (TI) stimulation is a recently developed noninvasive neuromodulation technique that enables focal modulation of deep brain structures. In this randomized, double-blind study, we developed a theta-burst patterned TI protocol and evaluated its effects in patients with NT1.",[209],"Narcolepsy Type 1",{"date":142,"type":32},{"date":212,"type":32},"2026-08-01",{"date":214,"type":23},"2027-12",{"name":38,"class":39},{"id":217,"slug":218,"hasResults":12,"nctId":219,"briefTitle":220,"officialTitle":221,"acronym":222,"eligibilityCriteria":223,"healthyVolunteers":12,"sex":18,"minAge":72,"maxAge":73,"enrollmentInfo":224,"targetDuration":4,"studyType":50,"phases":226,"briefSummary":228,"conditions":229,"keywords":234,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":239,"startDateStruct":240,"completionDateStruct":242,"leadSponsor":244,"locationsCount":111},"100638093","phase-1-safety-and-efficacy-of-s103-cells-in-progressiverefractory-multiple-sclerosis-100638093","NCT07587125","Safety and Efficacy of S103 Cells in Progressive\u002FRefractory Multiple Sclerosis","Safety and Efficacy of S103 Cells in Patients With Progressive or Refractory Multiple Sclerosis：An Open-Label, Single-Arm, Exploratory Clinical Study","RESET-MS","Inclusion Criteria:\n\n1. Age ≥18 years and ≤75 years;\n2. The subject signs the informed consent form, is willing and able to comply with the protocol, complete the research assessments and return for follow-up;\n3. To be diagnosed with Multiple Sclerosis (MS) according to the 2017 McDonald criteria, specifically including Progressive MS (Primary Progressive MS \\[PPMS\\] or Secondary Progressive MS \\[SPMS\\]) or Relapsing-Remitting MS (RRMS);\n4. The subject must be assessed by the investigator as having progressive or refractory MS for which no effective standard therapy is available. For subjects with Relapsing MS (RMS), refractory\u002Fprogressive disease is defined as having experienced at least 2 clinical relapses within the past 2 years, or at least 1 clinical relapse within the past 1 year accompanied by at least one gadolinium-enhancing lesion on MRI within the past year, despite treatment with standard disease-modifying therapies (DMTs). In addition, the subject must have an Expanded Disability Status Scale (EDSS) score between 2.0 and 7.0, inclusive, at both screening and baseline;\n5. Male study participants must agree to take contraceptive measures during the treatment period and within 1 year after receiving study treatment, and are prohibited from donating sperm throughout the study period;\n6. Women of childbearing potential (WOCBP) must agree to take contraceptive measures during treatment and for at least 1 year after receiving study treatment. Participants must have a negative serum pregnancy test result during screening; a negative urine pregnancy test result must be confirmed before receiving CAR-T for the first time.\n\nExclusion Criteria:\n\nSubjects will be ineligible for inclusion in the study if they meet any of the following criteria prior to screening or at the baseline visit:\n\n1. The subject has any medical, psychological, or social condition that, in the investigator's opinion, may harm the subject, interfere with their ability to participate in the study, or result in poor protocol compliance;\n2. Female subjects who are pregnant or lactating, plans to become pregnant at any time within 12 months after receiving CAR-T cell treatment, or has a history of spontaneous or induced abortion within 4 weeks prior to screening;\n3. The subject has a clinically relevant active infection, such as sepsis, pneumonia, or a severe local abscess, or a serious infection requiring hospitalization or intravenous antibiotic treatment within 4 weeks prior to screening. Subjects are also excluded if they have a known immunodeficiency disorder including Human Immunodeficiency Virus (HIV), test positive for Hepatitis B surface antigen (HBsAg) or detectable Hepatitis B virus (HBV) DNA, test positive for Hepatitis C virus (HCV) antibody with detectable HCV RNA, test positive for syphilis during the screening period, or have an active or high-risk history of tuberculosis infection;\n4. The subject has previously received any Chimeric Antigen Receptor (CAR) T-cell therapy or other genetically modified cell therapies, or has a history of allogeneic hematopoietic stem cell transplantation (HSCT) or solid organ transplantation. Furthermore, subjects are excluded if they have received intravenous immunoglobulin (IVIG) or plasma exchange (PE) within 4 weeks prior to screening, or have received tocilizumab or eculizumab treatment within 3 months prior to screening;\n5. The subject is diagnosed with an active, severe autoimmune disease other than Multiple Sclerosis, such as Systemic Lupus Erythematosus or Rheumatoid Arthritis. This also includes the presence of other severe progressive neurodegenerative or central nervous system (CNS) disorders, such as Parkinson's disease, Alzheimer's disease, stroke, or active CNS tumors, that the investigator believes would confound the clinical assessment of Multiple Sclerosis. Additionally, a history of active malignancy within the past 5 years excludes the subject, with the exception of adequately treated basal cell or squamous cell carcinoma of the skin, or carcinoma in situ of the cervix;\n6. The subject exhibits specific laboratory abnormalities or organ dysfunction during the screening period, including elevated liver enzymes with AST or ALT greater than 1.5 times the upper limit of normal (ULN), total bilirubin greater than 1.5 times the ULN, or a Creatinine Clearance (CrCl) of less than 60 mL\u002Fmin. Exclusions also apply for an absolute neutrophil count (ANC) of less than 2.0 × 10\\^9\u002FL, a platelet count of less than 100 × 10\\^9\u002FL, hemoglobin levels below 100 g\u002FL, or severe cardiovascular or pulmonary diseases, which include a Left Ventricular Ejection Fraction (LVEF) below 50%, unstable angina or myocardial infarction within the past 6 months, or a resting peripheral blood oxygen saturation (SpO2) of 91% or less;\n7. The subject has a known severe allergy, hypersensitivity, or intolerance to fludarabine, cyclophosphamide, or any excipients contained in the S103 CAR-T cell product, such as human serum albumin. Subjects are also excluded if they have received any live attenuated vaccine within 6 weeks prior to screening, or plan to receive a live vaccine during the study period.",{"count":225,"type":23},9,[227],"PHASE1","This study is a single-center, open-label, single-arm, exploratory clinical study to evaluate the safety, tolerability, and preliminary efficacy of S103（BCMA-CAR T ）cells in the treatment of progressive or refractory multiple sclerosis. The study is a dose escalation trial in adult progressive and refractory MS patients. A standard \"3+3\" design will be used to perform dose escalation to explore the safety profile and dose-limiting toxicities (DLTs). A total of 9 MS patients who meet the inclusion criteria are expected to be recruited.",[230,231,232,233],"Multiple Sclerosis (MS) Primary Progressive","Multiple Sclerosis","Multiple Sclerosis (MS) Secondary Progressive","Refractory Multiple Sclerosis",[231,235,233,236,237,238],"Progressive Multiple Sclerosis","BCMA-CAR T Cells","Chimeric Antigen Receptor T-Cell Therapy","Safety and Efficacy",{"date":142,"type":32},{"date":241,"type":32},"2026-05-08",{"date":243,"type":23},"2029-11",{"name":38,"class":39},{"id":246,"slug":247,"hasResults":12,"nctId":248,"briefTitle":249,"officialTitle":250,"acronym":251,"eligibilityCriteria":252,"healthyVolunteers":12,"sex":18,"minAge":72,"maxAge":253,"enrollmentInfo":254,"targetDuration":4,"studyType":50,"phases":256,"briefSummary":258,"conditions":259,"keywords":261,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":265,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":270,"locationsCount":111},"100634123","phase-2-transcutaneous-electrical-acupoint-stimulation-at-jing-well-points-for-disorders-of-consciousness-100634123","NCT07535593","Transcutaneous Electrical Acupoint Stimulation at Jing-Well Points for Disorders of Consciousness","Efficacy and Safety of Transcutaneous Electrical Acupoint Stimulation at Hand Jing-Well Points in Patients With Disorders of Consciousness：A Multicenter Randomized Controlled Trial","Wells-DoC II","Inclusion Criteria:\n\n* Age: 18-80 years old;\n* From 7 to 90 days since brain injury;\n* Diagnosed in VS\u002FUWS or MCS as defined by at least two CRS-R assessments performed during the screening period\n* Acquired cerebral damage of known etiology\n* Intact hand skin\n* Informed consent given by the legal surrogate\n\nExclusion Criteria:\n\n* Patients who continuously receive sedative drugs and Na+ or Ca2+ channel blockers (e.g., carbamazepine) or NMDA receptor antagonists (e.g., dextromethorphan)\n* History of previous serious、progressive neurological disorder prior to the brain injury;\n* Epilepsy and seizure\n* Unstable vital signs or life-threatening comorbidities\n* Implanted devices: including cardiac pacemakers or implantable cardioverter-defibrillators (ICDs), deep brain stimulators, ventriculoperitoneal (VP) shunts, and other indwelling electronic or neurosurgical implants.\n* Documented pregnancy","80 Years",{"count":255,"type":23},160,[77,257],"PHASE3","Effective treatment options for disorders of consciousness (DoC) remain limited, and available interventions show heterogeneous efficacy. To date, limited evidences support the use of amantadine and transcranial direct current stimulation in this population.\n\nBloodletting puncture (BP) at the hand twelve Jing-Well points (HTWPs) has been traditionally used in China as an empirical therapy for DoC; however, its efficacy has not been established by robust clinical evidence. Transcutaneous electrical acupoint stimulation (TEAS) provides a modern, noninvasive alternative for acupoint stimulation. The Wells-DoC trial, a multicenter, randomized, controlled, open-label study with blinded endpoint assessment, provided preliminary evidence that TEAS applied at the hand twelve Jing-Well points was associated with a numerically higher proportion of consciousness improvement in patients with DoC, although the difference did not reach statistical significance. These findings support the need for further evaluation in an adequately powered randomized controlled trial.\n\nThe Wells-DoC II trial is a multicenter, randomized, controlled, double-blind clinical trial designed to evaluate the efficacy and safety of TEAS at the twelve Jing-Well points of the hand in patients with DoC. The primary objective of the Wells-DoC II trial is to determine whether TEAS applied at the twelve Jing-Well points of the hand improves consciousness in adults with DoC. The primary endpoint is the proportion of patients achieving consciousness improvement after 14 consecutive days of treatment, compared between the TEAS group and the sham stimulation (placebo control) group.\n\nThe secondary objectives are to assess the effects of TEAS versus sham stimulation on: (1) changes in Coma Recovery Scale-Revised (CRS-R) scores at 7 and 14 days; (2) change in ABCD model classification at day 14; and (3) functional outcomes measured by the Glasgow Outcome Scale-Extended (GOSE) at 3 and 6 months after enrollment.\n\nA total of 160 patients will be recruited over a 28-month period.",[260],"Disorders of Consciousness Due to Severe Brain Injury",[262,263,264],"Transcutaneous Electrical Acupoint Stimulation","Hand Jing-Well Points","Disorders of Consciousness",{"date":142,"type":32},{"date":267,"type":32},"2026-04-20",{"date":269,"type":23},"2028-12",{"name":38,"class":39},{"id":272,"slug":273,"hasResults":12,"nctId":274,"briefTitle":275,"officialTitle":276,"acronym":4,"eligibilityCriteria":277,"healthyVolunteers":17,"sex":18,"minAge":72,"maxAge":73,"enrollmentInfo":278,"targetDuration":4,"studyType":50,"phases":280,"briefSummary":281,"conditions":282,"keywords":284,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":287,"startDateStruct":288,"completionDateStruct":290,"leadSponsor":291,"locationsCount":111},"100616583","effect-of-postoperative-analgesia-of-oliceridine-fumarate-for-gastrointestinal-function-recovery-in-patients-undergoing-lumbar-spine-surgery-100616583","NCT07307495","Effect of Postoperative Analgesia of Oliceridine Fumarate for Gastrointestinal Function Recovery in Patients Undergoing Lumbar Spine Surgery","Effect of Postoperative Analgesia of Oliceridine Fumarate for Gastrointestinal Function Recovery in Patients Undergoing Lumbar Spine Surgery:A Prospective, Multicenter, Double-blind,Randomized Controlled Study","Inclusion Criteria:\n\n* Age between 18 and 75 years old;\n* Patients undergoing lumbar surgery under general anesthesia (within 3 segments) and expected to receive postoperative patient-controlled analgesia;\n* ASA classification I-III;\n* BMI between 18 and 30 kg\u002Fm²;\n* Informed consent obtained from the patient.\n\nExclusion Criteria:\n\n* Use of any painkillers within 3 days before surgery; or long-term treatment with non-steroidal anti-inflammatory drugs (NSAIDs), defined as: within 3 months before surgery, use of NSAIDs daily for more than 2 consecutive weeks;\n* Presence of intestinal obstruction or suspicious symptoms: nausea and vomiting, abdominal bloating and pain, cessation of gas or bowel movements within the past two weeks, imaging suggesting intestinal dilation, or large amounts of air-fluid levels;\n* Patients with severe liver dysfunction (based on Child-Pugh classification, grade C);\n* History of or planned gastrointestinal surgery;\n* Patients allergic to the study drug;\n* Pregnant or breastfeeding patients;\n* QTcF abnormalities, males \\>450 ms, females \\>470 ms;\n* Participation in other drug trials within the past 30 days;\n* Long-term use of opioids (defined as: within 12 months before surgery, use for more than 1 month, more than 3 days per week, with daily doses exceeding 15 mg morphine equivalent);\n* Pre-existing neurological or psychiatric disorders: such as epilepsy, depression, schizophrenia, etc.;\n* Patients deemed unsuitable for this study by the investigator.",{"count":279,"type":23},428,[52],"Osemitidine fumarate is a novel G protein-biased ligand μ-opioid receptor agonist. Previous studies have confirmed its potent analgesic effects and safety: compared with morphine, it reduces respiratory depression and gastrointestinal dysfunction. This study aims to evaluate the effects of osemitidine on postoperative gastrointestinal function recovery and pain in patients undergoing lumbar spine surgery through a multicenter, double-blind, randomized controlled trial.",[283],"Oliceridine Fumarate",[285,286],"lumbar spine surgery","gastrointestinal function recovery",{"date":142,"type":32},{"date":289,"type":32},"2026-03-30",{"date":127,"type":23},{"name":38,"class":39},{"id":293,"slug":294,"hasResults":12,"nctId":295,"briefTitle":296,"officialTitle":297,"acronym":4,"eligibilityCriteria":298,"healthyVolunteers":12,"sex":18,"minAge":72,"maxAge":4,"enrollmentInfo":299,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":301,"conditions":302,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":305,"startDateStruct":307,"completionDateStruct":309,"leadSponsor":310,"locationsCount":111},"100611366","postoperative-delirium-in-patients-undergoing-cardiac-surgery-100611366","NCT07239648","Postoperative Delirium in Patients Undergoing Cardiac Surgery","A Real-World Single-Center Bidirectional Cohort Study on Postoperative Delirium in Patients Undergoing Cardiac Surgery","Inclusion Criteria:\n\n1. 18 years old and above\n2. Patients undergoing elective cardiac surgery\n\nExclusion Criteria:\n\n1. Organ transplantation surgery\n2. Pregnant patients\n3. Diagnosed with dementia or mental illness (such as schizophrenia) before surgery",{"count":300,"type":23},1500,"Establish a follow-up database for postoperative delirium in cardiac surgery patients, adopt a bidirectional cohort design to simultaneously analyze the associations between \"preoperative exposure factors and postoperative delirium incidence\" and \"postoperative delirium and long-term adverse outcomes\", and clarify the predictive factors and prognostic impacts of postoperative delirium.",[303],"Postoperative Delirium","2026-08-02",{"date":306,"type":32},"2026-08-04",{"date":308,"type":32},"2025-10-31",{"date":127,"type":23},{"name":38,"class":39},{"id":312,"slug":313,"hasResults":12,"nctId":314,"briefTitle":315,"officialTitle":316,"acronym":317,"eligibilityCriteria":318,"healthyVolunteers":12,"sex":18,"minAge":72,"maxAge":4,"enrollmentInfo":319,"targetDuration":4,"studyType":50,"phases":321,"briefSummary":322,"conditions":323,"keywords":325,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":330,"startDateStruct":331,"completionDateStruct":333,"leadSponsor":335,"locationsCount":111},"100563726","phase-3-dexmedetomidine-in-reducing-postoperative-delirium-in-cardiac-surgery-patients-100563726","NCT06619912","Dexmedetomidine in Reducing Postoperative Delirium in Cardiac Surgery Patients","Dexmedetomidine in Reducing Postoperative Delirium in Cardiac Surgery Patients：a Single-center, Double- Blind, Controlled Trial","DREAMS","Inclusion Criteria:\n\n1. Aged 18 years or older.\n2. Cardiac surgery with cardiopulmonary bypass.\n3. Ability to provide consent.\n\nExclusion Criteria:\n\n1. Preoperative schizophrenia, epilepsy, Parkinson's disease, myasthenia gravis, history of neurosurgery, or Mini-mental State Examination(MMSE) score: illiteracy\\\u003C17, primary school level\\\u003C20, high school level \\\u003C24.\n2. Patients with sick sinus syndrome, severe sinus bradycardia (heart rate\\\u003C50 beats\u002Fminute), grade II or above atrioventricular block, and no pacemaker implanted.\n3. Unable to communicate due to coma, severe dementia, or language barriers prior to surgery.\n4. Patients with severe liver dysfunction (Child Pugh C grade), renal dysfunction (preoperative dialysis), ASA grade V or expected survival ≤ 24 hours.\n5. Heart transplant surgery\n6. Surgery for congenital heart disease.\n7. Deep hypothermic circulatory arrest surgery.\n8. Already enrolled in other study patients.\n9. Refuse to participate.",{"count":320,"type":23},686,[257],"Delirium is a common consequence of cardiac surgery and associates with poor outcomes. Multiple causes can trigger delirium occurence, and it has been hypothesised that sleep disturbances can be one of them. Dexmedetomidine may be effective in reducing delirium. The aim of this study was to demonstrate preoperative dexmedetomidine nasal spray in cardiac surgery patients can reduce postoperative delirium by improving preoperative sleep.",[303,324],"Preoperative Sleep Disorder",[326,327,328,329],"postoperative delirium","preoperative sleep disorder","dexmedetomidine","cardiopulmonary coupling",{"date":142,"type":32},{"date":332,"type":32},"2025-03-03",{"date":334,"type":23},"2027-03-30",{"name":38,"class":39},{"id":337,"slug":338,"hasResults":12,"nctId":339,"briefTitle":340,"officialTitle":341,"acronym":4,"eligibilityCriteria":342,"healthyVolunteers":12,"sex":18,"minAge":156,"maxAge":203,"enrollmentInfo":343,"targetDuration":4,"studyType":50,"phases":345,"briefSummary":346,"conditions":347,"keywords":352,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":356,"lastUpdatePostDateStruct":357,"startDateStruct":359,"completionDateStruct":361,"leadSponsor":363,"locationsCount":111},"100522431","effect-of-platelet-rich-plasma-prp-injection-on-knee-osteoarthritis-100522431","NCT06082531","Effect of Platelet-rich Plasma (PRP) Injection on Knee Osteoarthritis","Therapeutic Effect of Platelet-rich Plasma (PRP) Injection on Knee Osteoarthritis and Periarticular Tissue Injury","Inclusion Criteria:\n\n* The age range of the participants was 20 to 60 years old. Through a comprehensive clinical and imaging examination, it was conclusively determined that the individuals had knee osteoarthritis or experienced injuries to the cart, and meniscus surrounding the knee joint.\n* The preoperative routine tests and examinations revealed no contraindications.\n* Revised sentence: \"Informed consent of the patient\n\nExclusion Criteria:\n\n* The platelet count or function exhibits significant abnormalities、Systemic infection transmitted through the bloodstream.\n* Prolonged usage of anti-inflammatory drugs and systemic corticoid administration.\n* In injection site or damage to the skin.\n* Patients with tumors or undergoing radiotherapy and chemotherapy.\n* Pregnant or breastfeeding women.\n* Individuals with mental illnesses who are unable to cooperate with follow-up procedures.\n* Contraindications for MRI、Patients or their families do consent to participate in the study.\n* Other circumstances that render participation in the study unsuitable.",{"count":344,"type":23},300,[52],"To evaluate the safety and effectiveness of PRP injection therapy in the repair of osteoarthritis and periarticular soft tissue injury through a single-center, exploratory clinical study, and to provide a more reliable basis for the treatment of joint injury.",[348,349,350,351],"Platelets-rich Plasma","Osteoarthritis Knees Both","Meniscus Disorder","Cartilage Injury",[353,354,351,355],"platelets-rich plasma","Osteoarthritis","Meniscus Injury","2026-07-28",{"date":358,"type":32},"2026-07-30",{"date":360,"type":32},"2023-09-01",{"date":362,"type":23},"2026-12-31",{"name":38,"class":39},{"id":365,"slug":366,"hasResults":12,"nctId":367,"briefTitle":368,"officialTitle":369,"acronym":4,"eligibilityCriteria":370,"healthyVolunteers":12,"sex":18,"minAge":371,"maxAge":372,"enrollmentInfo":373,"targetDuration":4,"studyType":50,"phases":375,"briefSummary":376,"conditions":377,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":356,"lastUpdatePostDateStruct":381,"startDateStruct":382,"completionDateStruct":384,"leadSponsor":385,"locationsCount":111},"100508097","researching-the-useful-of-barb-suture-in-obese-patients-undergoing-posterior-cervical-surgery-100508097","NCT05895968","Researching the Useful of Barb Suture in Obese Patients Undergoing Posterior Cervical Surgery","A Controlled Clinical Study on the Safety and Effectiveness of Barb Suture in Obese Patients Undergoing Posterior Cervical Surgery","Inclusion Criteria:\n\n* Symptoms and signs of the patients were typical. MRI showed single or multiple central herniation of C3-C7 intervertebral discs or spinal stenosis at corresponding levels, which confirmed cervical myeloid cervical spondylosis or cervical spinal stenosis.\n* Preoperative routine tests and examinations showed no contraindications.\n* BMI≥28\n* Informed consent was obtained from the patient and his family, informed consent was signed, and a complete follow-up was completed after surgery.\n\nExclusion Criteria:\n\n* A history of wasting diseases associated with malignancy and chemoradiotherapy that may interfere with wound healing\n* History of dermatosis\n* History of immune system diseases\n* History of blood diseases\n* Skin injury or defect at the back of the neck\n* Severe hypersensitivity\n* Cold, fever, trauma or other infections in the week before surgery\n* Infectious disease\n* Psychosis could not cooperate with follow-up","28 Years","85 Years",{"count":374,"type":23},60,[52],"Through a single-center, exploratory clinical study, the safety and effectiveness of using barb wire in the incision and suture of posterior cervical surgery in obese patients were evaluated, providing a basis for its wide clinical application in posterior cervical surgery.",[378,379,380],"Cervical Spinal Stenosis","Posterior Cervical Spine Surgery","Barbed Suture",{"date":358,"type":32},{"date":383,"type":32},"2023-01-01",{"date":362,"type":23},{"name":38,"class":39},{"id":387,"slug":388,"hasResults":12,"nctId":389,"briefTitle":390,"officialTitle":391,"acronym":4,"eligibilityCriteria":392,"healthyVolunteers":12,"sex":18,"minAge":371,"maxAge":372,"enrollmentInfo":393,"targetDuration":4,"studyType":50,"phases":394,"briefSummary":395,"conditions":396,"keywords":400,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":356,"lastUpdatePostDateStruct":403,"startDateStruct":404,"completionDateStruct":406,"leadSponsor":407,"locationsCount":111},"100499673","study-of-individualized-precise-and-standardized-cervical-open-door-surgery-for-cervical-spinal-stenosis-100499673","NCT05786313","Study of Individualized, Precise and Standardized Cervical Open-door Surgery for Cervical Spinal Stenosis","Prospective Controlled Clinical Study of Individualized, Precise and Standardized Posterior Cervical Open-door Surgery for Cervical Spinal Stenosis","Inclusion Criteria:\n\n* The age of 28-85 years old; Through systematic clinical and imaging examination, patients diagnosed with C3-7 multilevel cervical spondylitis myelopathy or cervical spinal stenosis who need to undergo posterior cervical open-door surgery.\n* No contraindications in preoperative routine tests and examinations.\n* Informed consent of patients.\n\nExclusion Criteria:\n\n* Cervical radiculopathy\n* Cervical kyphosis or instability\n* Cervical spondylosis caused by trauma, tumor, tuberculosis and metabolic diseases\n* Revision surgery or combined anterior-posterior surgery is required\n* Serious neurological diseases affect the postoperative effect evaluation\n* Mental illness cannot cooperate with follow-up\n* Contraindications for MRI examination\n* Patients themselves or their families do not agree to participate in the study\n* Other situations that are not suitable for study participation.",{"count":97,"type":23},[52],"To evaluate the safety and effectiveness of individualized, precise and standardized open-door posterior cervical surgery through a single-center, exploratory clinical study, so as to provide a more reliable basis for the treatment of cervical spinal stenosis.",[378,397,398,399],"Cervical Spinal Cord Injury","Individuation","Standardization",[401,402],"cervical spinal stenosis","open angle",{"date":358,"type":32},{"date":405,"type":32},"2023-03-01",{"date":362,"type":23},{"name":38,"class":39},{"id":409,"slug":410,"hasResults":12,"nctId":411,"briefTitle":412,"officialTitle":413,"acronym":4,"eligibilityCriteria":414,"healthyVolunteers":12,"sex":18,"minAge":72,"maxAge":415,"enrollmentInfo":416,"targetDuration":4,"studyType":50,"phases":417,"briefSummary":418,"conditions":419,"keywords":420,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":356,"lastUpdatePostDateStruct":423,"startDateStruct":424,"completionDateStruct":425,"leadSponsor":426,"locationsCount":111},"100498200","correlation-between-parameters-and-prognosis-of-cervical-single-open-door-surgery-100498200","NCT05767164","Correlation Between Parameters and Prognosis of Cervical Single Open-door Surgery","Correlation Between Parameters and Prognosis of Cervical Single Open-door Surgery: a Multicenter Retrospective Clinical Study","Inclusion Criteria:\n\n* Symptoms and signs of the patients were typical. MRI showed single or multiple central herniation of C3-C7 intervertebral discs or spinal stenosis at corresponding levels, which confirmed cervical myeloid cervical spondylosis or cervical spinal stenosis.\n* Conservative treatment for more than 3 months before surgery was ineffective.\n* The patients underwent cervical single open-door surgery.\n* Informed consent was obtained from the patient and his family, informed consent was signed, and a complete follow-up was completed after surgery\n\nExclusion Criteria:\n\n* Cervical spondylotic radiculopathy.\n* Cervical kyphosis or instability.\n* Cervical spondylosis caused by trauma, tumor, tuberculosis and metabolic diseases.\n* Revision surgery or combined anterior-posterior surgery is required.\n* The patients had severe neurological diseases affecting the evaluation of postoperative results.\n* Psychopath.\n* MRI or CT for contraindications.","86 Years",{"count":97,"type":23},[52],"The aim of study was evaluated the relationship between the relevant evaluation indexes of cervical spine open-door surgery, prognosis and complication rate, and provided theoretical basis for personalized surgical program through multi-center retrospective clinical study",[378],[421,378,422],"Cervical single open-door surgery","Open angle",{"date":358,"type":32},{"date":383,"type":32},{"date":362,"type":23},{"name":38,"class":39},{"id":428,"slug":429,"hasResults":12,"nctId":430,"briefTitle":431,"officialTitle":431,"acronym":432,"eligibilityCriteria":433,"healthyVolunteers":12,"sex":18,"minAge":157,"maxAge":4,"enrollmentInfo":434,"targetDuration":436,"studyType":24,"phases":4,"briefSummary":437,"conditions":438,"keywords":440,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":356,"lastUpdatePostDateStruct":444,"startDateStruct":445,"completionDateStruct":447,"leadSponsor":449,"locationsCount":450},"100441721","antithrombotic-drug-use-in-patients-with-ischemic-stroke-and-microbleeds-100441721","NCT05032053","Antithrombotic Drug Use in Patients With Ischemic Stroke and Microbleeds","AIM-2","Inclusion Criteria:\n\n1. Patients diagnosed clinically as ischemic stroke;\n2. Age ≥ 40 years;\n3. Onset time ≤ 3 months;\n4. Informed consent was signed.\n\nExclusion Criteria:\n\n1. Patients with symptomatic intracranial hemorrhage;\n2. bleeding lesion \\> 10 mm was found on SWI;\n3. Vascular malformations, tumors, abscesses or other major non ischemic brain diseases were present;\n4. There are contraindications for antithrombotic drugs use;\n5. Serious systemic diseases;\n6. Refusal to sign informed consent or poor compliance.",{"count":435,"type":23},3000,"1 Year","To observe the effect of different antithrombotic drugs on the prognosis of ischemic stroke patients with cerebral microbleeds. And further combined with proteomic methods to explore serological markers that can be used to accurately predict the prognosis of such patients.",[439],"Ischemic Stroke",[439,441,442,443],"microbleeds","Proteomics","antithrombotic drug",{"date":358,"type":32},{"date":446,"type":32},"2022-03-01",{"date":448,"type":23},"2027-12-01",{"name":38,"class":39},16,{"id":452,"slug":453,"hasResults":12,"nctId":454,"briefTitle":455,"officialTitle":456,"acronym":457,"eligibilityCriteria":458,"healthyVolunteers":12,"sex":18,"minAge":72,"maxAge":372,"enrollmentInfo":459,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":461,"conditions":462,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":463,"lastUpdatePostDateStruct":464,"startDateStruct":465,"completionDateStruct":467,"leadSponsor":469,"locationsCount":89},"100624140","early-neurovascular-decoupling-trajectories-after-revascularization-in-acute-ischemic-stroke-100624140","NCT07405762","Early Neurovascular Decoupling Trajectories After Revascularization in Acute Ischemic Stroke","Mechanisms of Recovery Phenotypes: Early Neurovascular Decoupling Trajectories After Revascularization in Acute Ischemic Stroke Using Multimodal Monitoring","MAP-END","Inclusion Criteria:\n\n1. Age between 18 and 85 years\n2. Acute ischemic stroke due to occlusion of the anterior circulation large vessel (terminal internal carotid artery, or M1\u002FM2 segment of the middle cerebral artery), confirmed by computed tomography angiography (CTA) or magnetic resonance angiography (MRA).\n3. Underwent endovascular thrombectomy with successful reperfusion, defined as a post-procedural modified Thrombolysis in Cerebral Infarction (mTICI) grade of 2b or 3.\n4. Time from symptom onset to femoral artery puncture is ≤ 24 hours.\n5. Written informed consent is provided by the patient or their legally authorized representative.\n\nExclusion Criteria:\n\n1. Pre-stroke disability defined as a modified Rankin Scale (mRS) score ≥ 2.\n2. Severe impairment of consciousness within 24 hours post-thrombectomy, defined as a Glasgow Coma Scale (GCS) score ≤ 8.\n3. Inadequate temporal bone window preventing acquisition of stable blood flow signals by Transcranial Doppler (TCD).\n4. Conditions that may significantly compromise electroencephalography (EEG) quality, such as history of significant traumatic brain injury, skull defect, or intracranial metallic devices.\n5. Conditions that may invalidate F-wave studies, including peripheral neuropathy, cervical radiculopathy, or primary disease of the target muscles.\n6. Concurrent severe organ failure, malignancy, or a life expectancy of less than 3 months.\n7. Pregnancy or lactation.",{"count":460,"type":23},180,"Background:\n\nRecanalization therapy is the standard treatment for acute ischemic stroke (AIS), yet patient outcomes remain highly heterogeneous. The underlying mechanisms of this variability are not fully understood. Neurovascular coupling (NVC), the tight link between neural activity and cerebral blood flow, is fundamental for brain function. Its disruption (neurovascular decoupling) after stroke is hypothesized to be a key determinant of recovery, but its dynamic early trajectory and predictive value for long-term functional recovery are poorly characterized.\n\nPurpose:\n\nThis observational study aims to delineate the early trajectory of neurovascular decoupling following endovascular thrombectomy in AIS patients and to investigate its association with long-term functional outcome. We seek to construct a single composite biomarker by integrating multimodal data, and to evaluate its predictive value for 90-day recovery.\n\nMethods:\n\nA prospective cohort of AIS patients who undergo successful endovascular thrombectomy will be enrolled. Multimodal monitoring will be performed at specific early time points: within Days 1-3 and at Day 7 post-procedure. Assessments include: Transcranial Doppler (TCD) for cerebral hemodynamics, Electroencephalography (EEG) for neural activity, and F-wave studies for spinal motoneuron excitability. Clinical severity will be assessed using the National Institutes of Health Stroke Scale (NIHSS) concurrently. The primary outcome is the early trajectory of a composite neurovascular decoupling index. The key predictive relationship between this trajectory and 90-day functional status (assessed using the modified Rankin Scale, mRS) will be evaluated.\n\nSignificance:\n\nThis study will provide novel insights into the early neurophysiological changes following successful thrombectomy. By defining the trajectory of neurovascular decoupling in the critical first week and linking it to long-term function, the findings may contribute to the development of early predictive models and guide personalized rehabilitation strategies.",[439],"2026-07-16",{"date":145,"type":32},{"date":466,"type":32},"2026-02-05",{"date":468,"type":23},"2028-09-05",{"name":38,"class":39},{"id":471,"slug":472,"hasResults":12,"nctId":473,"briefTitle":474,"officialTitle":475,"acronym":4,"eligibilityCriteria":476,"healthyVolunteers":12,"sex":18,"minAge":203,"maxAge":4,"enrollmentInfo":477,"targetDuration":4,"studyType":50,"phases":479,"briefSummary":480,"conditions":481,"keywords":4,"overallStatus":141,"whyStopped":4,"lastUpdateSubmitDate":483,"lastUpdatePostDateStruct":484,"startDateStruct":486,"completionDateStruct":488,"leadSponsor":490,"locationsCount":111},"100644210","the-effect-of-esketamine-on-postoperative-cognitive-function-in-elderly-patients-undergoing-oral-and-maxillofacial-surgery-100644210","NCT07665099","The Effect of Esketamine on Postoperative Cognitive Function in Elderly Patients Undergoing Oral and Maxillofacial Surgery","Effect of Esketamine on Postoperative Cognitive Function in Elderly Patients Undergoing Oral and Maxillofacial Surgery: A Prospective, Randomized, Double-Blind, Placebo-Controlled Parallel Clinical Trial","Inclusion Criteria:\n\nAge ≥ 60 years, either sex; Scheduled for elective oral and maxillofacial surgery under general anesthesia (including oral and maxillofacial tumor surgery, orthognathic surgery, and maxillofacial trauma repair surgery); American Society of Anesthesiologists (ASA) physical status I-III; Expected duration of anesthesia ≥ 2 hours; Willing and able to provide written informed consent.\n\nExclusion Criteria:\n\nPre-existing behavioral disorders or psychiatric diseases (e.g., Alzheimer's disease, Parkinson's disease), or current use of antipsychotic medications (e.g., clozapine, risperidone, olanzapine, haloperidol, chlorpromazine); Pre-existing severe organ dysfunction including: severe cardiovascular disease (life-threatening arrhythmias, severe uncontrolled hypertension, coronary artery disease, heart failure), severe respiratory disease (respiratory failure, severe chronic obstructive pulmonary disease), severe hepatic insufficiency (Child-Pugh Class C), or severe renal insufficiency (glomerular filtration rate \\\u003C 30 mL\u002Fmin or creatinine \\> 2.5 mg\u002FdL); Known contraindications to esketamine including: hypersensitivity to the active substance or any excipients; severe risk of elevated blood pressure or intracranial pressure; uncontrolled or untreated hypertension (resting systolic\u002Fdiastolic blood pressure \\> 180\u002F100 mmHg); preeclampsia or eclampsia; untreated or inadequately treated hyperthyroidism; conditions requiring uterine relaxation (e.g., uterine rupture, umbilical cord prolapse); use as the sole anesthetic in patients with significant ischemic heart disease; Surgical approach that would interfere with postoperative MoCA assessment; Concurrent participation in another clinical trial; Pre-existing cognitive impairment or Mini-Mental State Examination (MMSE) score \\\u003C 24, unable to complete questionnaire-based assessments.",{"count":478,"type":23},98,[52],"Esketamine is a common anesthetic adjuvant. Previous studies have shown that it may have protective effects on the brain. This study aims to investigate whether esketamine can improve cognitive function recovery in elderly patients (aged 60 years and older) undergoing oral and maxillofacial surgery.\n\nParticipants will be randomly assigned to receive either esketamine or a placebo (normal saline) during anesthesia. Neither the participants nor the researchers will know which treatment is given.\n\nCognitive function will be assessed using standardized tests before surgery and at 1, 3, 7, and 15 days after surgery. Sleep quality, pain scores, emotional status, and adverse events will also be recorded. Blood samples will be collected to explore potential mechanisms.\n\nThe study is expected to enroll approximately 98 participants at the Third Affiliated Hospital of Air Force Medical University in Xi'an, China. Participation will last about 16 days from the day before surgery to the final follow-up on day 15 after surgery.",[482],"Perioperative Neurocognitive Disorders","2026-06-18",{"date":485,"type":32},"2026-06-24",{"date":487,"type":23},"2026-07-01",{"date":489,"type":23},"2027-01-31",{"name":38,"class":39},{"id":492,"slug":493,"hasResults":12,"nctId":494,"briefTitle":495,"officialTitle":496,"acronym":4,"eligibilityCriteria":497,"healthyVolunteers":12,"sex":18,"minAge":72,"maxAge":498,"enrollmentInfo":499,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":501,"conditions":502,"keywords":4,"overallStatus":141,"whyStopped":4,"lastUpdateSubmitDate":504,"lastUpdatePostDateStruct":505,"startDateStruct":507,"completionDateStruct":508,"leadSponsor":510,"locationsCount":4},"100641382","clinical-study-on-the-efficacy-of-laparoscopic-assisted-open-surgery-through-subclavian-approach-for-unilateral-thyroid-cancer-100641382","NCT07654322","Clinical Study on the Efficacy of Laparoscopic Assisted Open Surgery Through Subclavian Approach for Unilateral Thyroid Cancer","Multicenter Prospective Cohort Clinical Study on the Efficacy of Pneumoperitoneum-Free, Subclavian Transaxillary Laparoscopic-Assisted Versus Open Surgery for Unilateral Thyroid Cancer","Inclusion Criteria:\n\n1. Patients with newly diagnosed thyroid cancer aged ≥ 18 years and ≤ 70 years old;\n2. According to the latest ATA guidelines for the diagnosis and treatment of thyroid nodules and thyroid cancer in China, papillary thyroid carcinoma confirmed by histopathology has a clinical staging of cN0 in cervical lymph nodes.\n3. The patient has unilateral thyroid cancer with T1-T2 stage tumors, no lymph node metastasis, no extraglandular invasion, and no distant metastasis. They are willing to undergo surgical treatment for thyroid cancer;\n4. The surgical method is determined through joint consultation between the patient and the doctor;\n5. Participants voluntarily join this study and sign an informed consent form.\n\nExclusion Criteria:\n\n1. Age\\>70 years old;\n2. Initial diagnosis of stage III-IV thyroid cancer;\n3. Thyroid cancer accompanied by abnormal thyroid function;\n4. The heart, lung, liver, kidney and other important organs have abnormal functions, and diabetes with poor control cannot tolerate surgery;\n5. The researcher believes that the patient is not suitable to participate in any other circumstances of this study.","70 Years",{"count":500,"type":23},400,"This study compares the clinical efficacy of non inflatable subclavian endoscopic surgery and open surgery for unilateral thyroid cancer, aiming to compare the differences in lymph node dissection rate, complication rate, surgical time, hospitalization time, drainage tube placement time and other indicators between the two surgical procedures, and provide guidance for surgical selection and safety in the later stage.\n\nThis study is a clinical controlled trial that plans to include 400 consecutive patients with thyroid cancer. After being fully informed and signing the informed consent form, the subjects will enter the trial period after being screened and qualified. The subjects will undergo non inflatable subclavian endoscopic thyroidectomy or open subclavian thyroidectomy according to their own wishes. The enrollment period is from March 2026-2028. The follow-up period should be at least 5 years.\n\nAfter the start of the experiment, a recruitment notice and corresponding recruitment manual will be issued, with a planned recruitment of 100 patients. The preparation stage for clinical research should include the preparation, distribution, and confirmation of research documents, as well as personnel training; Sign the informed consent form and screen the subjects. The surgical method for thyroid cancer is determined by the surgeon based on the patient's condition and after communication with the patient Evaluate the number of lymph nodes and metastatic lymph nodes in the central area by the pathology department, organize the operation time according to the surgical records, calculate the patient's drainage volume and hospitalization time according to the nursing records, and conduct telephone follow-up on patient satisfaction in the later stage.\n\nEstablish individual patient information using the existing thyroid cancer database in the department, recording general information, diagnosis and treatment history, and other relevant data.",[503],"Thyroid Cancer","2026-06-12",{"date":506,"type":32},"2026-06-17",{"date":487,"type":23},{"date":509,"type":23},"2031-02-28",{"name":38,"class":39},{"id":512,"slug":513,"hasResults":12,"nctId":514,"briefTitle":515,"officialTitle":516,"acronym":4,"eligibilityCriteria":517,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":518,"targetDuration":519,"studyType":24,"phases":4,"briefSummary":520,"conditions":521,"keywords":4,"overallStatus":141,"whyStopped":4,"lastUpdateSubmitDate":523,"lastUpdatePostDateStruct":524,"startDateStruct":526,"completionDateStruct":528,"leadSponsor":530,"locationsCount":111},"100642432","a-real-world-hcm-cohort-trial-100642432","NCT07638033","A Real-world HCM-cohort Trial","A Multicenter, Prospective, Real-world Study on Hypertrophic Cardiomyopathy","Inclusion Criteria:\n\n1. Meet the clinical diagnostic criteria for HCM\\*;\n2. Patients who understand the purpose of this study, voluntarily participate in the trial and sign the informed consent form, have good compliance, and are willing to undergo clinical follow-up.\n\n   * Clinical diagnosis of HCM is defined as left ventricular wall thickness ≥15mm at any position during diastole by.echocardiography or CMR (≥13mm if there is a family history of HCM or positive cardiac genetic testing), and other secondary factors (such as severe hepertension, aortic stenosis) causing myocardial hypertrophy are excluded.\n\nExclusion Criteria:\n\n1. Metabolic syndrome or hypertrophic cardiomyopathy-like syndromes associated with left ventricular hypertrophy, such as amyloid cardiomyopathy, sarcoidosis, Fabry disease, Danon disease or Noonan syndrome;\n2. Severe systemic hypertension and\u002For severe aortic stenosis (\\\u003C1cm²);\n3. Comorbid malignant tumors;\n4. Comorbid with other end-stage diseases with an expected lifespan of less than 3 years;\n5. Comorbid with mental disorders;\n6. Currently participating in other clinical trials and not reaching the primary endpoint.",{"count":435,"type":23},"3 Years","Hypertrophic cardiomyopathy (HCM) is a genetically mediated myocardial disease predominantly caused by pathogenic mutations in sarcomeric protein genes and characterized by asymmetric left ventricular hypertrophy. Patients with HCM commonly present with dyspnea, chest pain, and exercise intolerance. Sudden cardiac death, progressive heart failure, and thromboembolic events remain the leading causes of mortality and morbidity, substantially impairing quality of life and increasing healthcare burden.\n\nDespite advances in understanding the pathophysiology, diagnosis, and management of HCM, significant challenges persist, including etiological heterogeneity and underdiagnosis. At present, dedicated and systematic HCM databases remain lacking in China. Establishing a nationally HCM cohort and disease-specific database is therefore of considerable importance. In alignment with the goals of the \"Healthy China 2030\" initiative and supported by advances in medical big data technologies.\n\nThis study aims to construct a comprehensive HCM cohort, evaluate contemporary diagnostic and therapeutic practices and patient prognosis, identify relevant risk factors, and ultimately improve the overall management of patients with HCM.",[522],"Hypertrophic Cardiomyopathy (HCM)","2026-06-04",{"date":525,"type":32},"2026-06-10",{"date":527,"type":23},"2026-06-30",{"date":529,"type":23},"2030-12-31",{"name":38,"class":39},{"id":532,"slug":533,"hasResults":12,"nctId":534,"briefTitle":535,"officialTitle":536,"acronym":537,"eligibilityCriteria":538,"healthyVolunteers":12,"sex":18,"minAge":72,"maxAge":253,"enrollmentInfo":539,"targetDuration":541,"studyType":24,"phases":4,"briefSummary":542,"conditions":543,"keywords":4,"overallStatus":141,"whyStopped":4,"lastUpdateSubmitDate":545,"lastUpdatePostDateStruct":546,"startDateStruct":548,"completionDateStruct":550,"leadSponsor":551,"locationsCount":111},"100638730","pulsed-field-ablation-versus-radiofrequency-ablation-effects-of-pulmonary-vein-isolation-combined-with-left-atrial-posterior-wall-isolation-on-postoperative-gastric-motility-in-patients-with-persistent-atrial-fibrillation-100638730","NCT07612241","Pulsed Field Ablation Versus Radiofrequency Ablation: Effects of Pulmonary Vein Isolation Combined With Left Atrial Posterior Wall Isolation on Postoperative Gastric Motility in Patients With Persistent Atrial Fibrillation","A Comparative Study on the Effects of Pulmonary Vein Isolation Combined With Left Atrial Posterior Wall Isolation Via Pulsed Field Ablation Versus Radiofrequency Ablation on Postoperative Gastric Motility in Patients With Persistent Atrial Fibrillation","PFA-GM","Inclusion Criteria:\n\n* Age 18-80 years\n* Diagnosed with persistent atrial fibrillation (AF) according to current guidelines\n* Undergoing first-time catheter ablation (PFA or RF) with planned pulmonary vein isolation plus left atrial posterior wall isolation\n* Able to understand and sign informed consent\n* Able to complete radionuclide gastric emptying scintigraphy and symptom questionnaires\n\nExclusion Criteria:\n\n* Previous AF ablation or cardiac surgery\n* History of gastroparesis or severe gastrointestinal disease\n* Prior upper gastrointestinal surgery\n* Use of prokinetic or antisecretory medications within 4 weeks before enrollment\n* Severe renal\u002Fhepatic dysfunction or active malignancy\n* Pregnant or breastfeeding women\n* Inability to comply with study procedures or follow-up",{"count":540,"type":23},20,"7 Days","This is a single-center, prospective, matched cohort study comparing the effect of Pulsed Field Ablation (PFA) versus Radiofrequency Ablation (RF) on postoperative gastric motility in patients with persistent atrial fibrillation (AF). A total of 20 patients will be enrolled in a 1:1 matched design (10 PFA, 10 RF), matched by age, gender, left atrial diameter, AF duration, and diabetes history. All patients will undergo pulmonary vein isolation (PVI) plus left atrial posterior wall isolation (LAPWI).\n\nThe primary outcome is gastric emptying assessed by radionuclide imaging preoperatively and at 48 hours post-ablation. Secondary outcomes include gastrointestinal symptom scores: PAGI-SYM, GSRS, and GerdQ measured before ablation and at 7 days post-procedure.\n\nPatients with prior AF ablation, upper gastrointestinal surgery, gastroparesis, or recent use of gastrointestinal medications are excluded. The study period is from January 30, 2026 to July 30, 2026.\n\nThis study aims to evaluate whether PFA is associated with better gastric motility preservation compared with conventional RF ablation in persistent AF patients undergoing extended PVI plus posterior wall isolation.",[544],"Persistent Atrial Fibrillation","2026-05-28",{"date":547,"type":32},"2026-06-02",{"date":549,"type":23},"2026-05-31",{"date":362,"type":23},{"name":38,"class":39},{"id":553,"slug":554,"hasResults":12,"nctId":555,"briefTitle":556,"officialTitle":557,"acronym":558,"eligibilityCriteria":559,"healthyVolunteers":12,"sex":18,"minAge":72,"maxAge":4,"enrollmentInfo":560,"targetDuration":4,"studyType":50,"phases":562,"briefSummary":563,"conditions":564,"keywords":569,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":575,"lastUpdatePostDateStruct":576,"startDateStruct":577,"completionDateStruct":579,"leadSponsor":581,"locationsCount":582},"100570077","phase-3-nitric-oxide-for-reduced-intensive-support-in-cardiac-surgery-with-cardiopulmonary-bypass-100570077","NCT06702553","Nitric Oxide for Reduced Intensive Support in Cardiac Surgery With Cardiopulmonary Bypass","Effect of Inhaled Nitric Oxide on Major Adverse Events Requiring Intensive Life Support in Adults Undergoing Cardiac Surgery With Cardiopulmonary Bypass: A Phase III, Double-Blind, Multicenter, Randomized Controlled Trial (Nitric Oxide for Reduced Intensive Support in Cardiac Surgery With Cardiopulmonary Bypass, the NORISC Trial)","NORISC","Inclusion Criteria:\n\n1. Age ≥18 years.\n2. Elective cardiac or aortic surgery requiring CPB\n3. Without history of previous open heart surgery.\n\nExclusion Criteria:\n\n1. Immediate emergency cardiac surgery;\n2. Cardiac surgery that requires deep hypothermic circulatory arrest;\n3. Planned cardiac surgery for congenital heart disease repair;\n4. Planned for heart transplatation\n5. Ongoing heart failure or low output syndrome already on intensive support (IABP, ECMO, left ventricular assist device such as impella, mechanical ventilation), left ventricular ejection fraction of \\\u003C 30% or comparable, equivalent preoperative conditions\n6. Already accepted or currently on inhaled NO therapy or inhaled\u002Faerosolized prostacyclin in the week prior to the enrollment;\n7. Endstage kidney disease with estimated glomerular filtration rate (eGFR) \\\u003C 15 ml\u002Fmin or already on renal replacement surgery.\n8. Hemophilia A or B\n9. Other terminal stage of chronic disease with life expectancy less than 1 year per evaluation and adjudication of the attending physicians.",{"count":561,"type":23},3650,[257],"Cardiac surgery is a procedure that is commonly performed worldwide. Despite these technological advances, cardiac surgery remains a high-risk surgery. Among post-operative complications, acute kidney injury, respiratory failure, myocardial infarction, and stroke as well as cognitive dysfunction are significant causes of mortality in patients undergoing and following cardiac surgery. Inhaled nitric oxide (NO) therapy as a selective pulmonary vasodilator in cardiac surgery has been one of the most significant pharmacological advances in managing pulmonary hemodynamics and life threatening right ventricular dysfunction and failure. In addition, newer applications show greater promise of inhaled NO as a therapy in the area of cardiac surgery associated acute kidney injury and ischemia reperfusion. However, this remarkable expectation to inhaled NO has experienced a roller-coaster ride with high hopes and nearly universal demonstration of physiological benefits but disappointing translation of these benefits to harder clinical outcomes, like mortality. Most of our understanding on the iNO field in cardiac surgery stems from small observational or single center randomized trials, which failed to ascertain strong evidence base. As a consequence, there are only week clinical practice guidelines on the field and only European expert opinion for the use of iNO in routine and more specialized cardiac surgery. There is need for a large multicenter randomized controlled study to confirm the administration of iNO as an effective weapon for the battle against life threatening complication in high risk cardiac surgical patients.\n\nIn a previous meta analysis with 27 studies included, we demonstrated that inhaled nitric oxide (NO) could reduce the duration of mechanical ventilation and reducing biomarkers of organ injury and clinical signs of organ dysfunction in cardiac surgery under cardiopulmonary bypass (CPB) , but had no significance in the ICU stay, hospital stay, and mortality. This may be attributed to the small sample size of the most included studies (of the 27 studies included, 20 studies with sample size less than 100) and heterogeneity in timing, dosage and duration of iNO administration. Well-designed, large-scale, multicenter clinical trials are needed to further explore the effect of iNO in improving postoperative prognosis in cardiovascular surgical patients.\n\nWe are planning a large multicenter controlled randomized trial to demonstrate that inhaled nitric oxide can reduce composite outcome of death and Major Adverse Events (MAEs), including need for intensive supports due to heart failure, low cardiac output sydrome, or renal failure, respiratory failure, etc., and myocardial infarction, stroke, and sepsis at 30 days after surgery from 20% to 16% in patient undergoing cardiac surgery with cardiopulmonary bypass.\n\nIf the hypothesis had been proved and validated, the results of this study can provide strong evidence for guidelines to facilitate the routine use of iNO in all cardiopulmonary bypass assisted cardiac procedures with 31,800 postoperative outcomes improved per year in US and in China.",[565,566,567,568],"Nitric Oxide","Cardiac Surgery","Cardiopulmonary Bypass","Adult Patients Undergoing Cardiovascular Surgery With Cardiopulmonary Bypass",[565,570,571,572,573,574],"cardiopulmonary bypass","major adverse events","cardiac surgery","complications","Organ protection","2026-05-26",{"date":190,"type":32},{"date":578,"type":32},"2025-05-19",{"date":580,"type":23},"2029-03-31",{"name":38,"class":39},3,""]